Thousands of Californians live with sickle cell disease, a painful blood disorder. But new treatments, including a promising form of gene therapy, are offering hope to ...
Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...
Azim, MD, MS, Division Chief Transplant and Cell Therapy/Hematological malignancies at Loma Linda University (LLU) Cancer ...
Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and ...
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an ...
For kids with the condition, day-to-day activities like going to school or playing with friends can lead to life-threatening ...
DURHAM, N.C. (WTVD) -- Duke Eye Center has become the first academic medical center in the country to implant a new ...
India Today on MSN
India's next leap: Homegrown biotech push spurs hope for affordable next-gen drugs for cancers, other serious conditions
The move follows similar initiatives by players like Syngene, Laurus Labs, and Aragen. Industry analysts see Bharat Biotech’s ...
The California Institute for Regenerative Medicine (CIRM) has awarded $9 million to Loma Linda University Health to create a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback